Clarity Pharmaceuticals (ASX:CU6) combined trastuzumab with its proprietary copper-chelating, or SAR, technology for the development of copper-67-based radioimmunotherapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients, according to a Tuesday Australian bourse filing.
Preclinical evidence showed a dose-response reduction in tumor size and prolonged survival using copper-67-SAR-trastuzumab compared to trastuzumab, an antibody that targets HER2, alone in a HER2-positive tumor mouse model, the filing said.
The firm collaborated with the University of Melbourne for the combination of the trastuzumab antibody with the SAR chelator and radiolabeling with copper-64 for diagnostic imaging, the filing added.
The firm plans to conduct a phase 1/2a theranostic study with copper-64 and copper-67 SAR trastuzumab in HER2-positive breast cancer patients, per the filing.
It also signed a supply agreement with EirGenix for the clinical development and future commercial supply of clinical-grade good manufacturing practice trastuzumab biosimilar, EG12014.
Its shares fell 6% in early trading on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.